April 23, 2024
Dupilumab for Eosinophilic Esophagitis
Article: Lancet Gastroenterol Hepatol. 2023 Nov;8(11):990-1004. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Reviewer: Dr. Kelly Squires